Study sites will enroll older, cognitively normal individuals (270 total) using APOE genotyping to enrich the enrollment sample such that roughly half of those scanned will have elevated amyloid brain scan results and half of those scanned will have not elevated amyloid results. From this enriched sample, participants (approximately 25% African-American) will all receive their Alzheimer's Disease Dementia Risk Assessment based on known risk factors. Half of the participants will be randomized to also learn their amyloid brain scan result at that time, while the other half will learn their scan result 6 months later. Cognitive, psychological, and behavioral outcomes will be compared between these two groups. Participants will be followed for up to 9 months with up to 7 in-person visits and 5 phone calls.